| (USD) | Sep 2023 | Q/Q |
|---|---|---|
| Revenue | 1.3MM | -100% |
| Operating Income | -113.8MM | -167% |
| Operating Expenses | 115.1MM | -7% |
| Net Income | -99.4MM | -154% |
| R&D | 89.7MM | -8% |
| G&A | 25.3MM | -3% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Denali Therapeutics (DNLI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Denali Therapeutics Inc. ( NASDAQ:DNLI ) shareholders should be happy to see the share price up 18% in the last month...
Denali (DNLI) reports lower than expected fourth-quarter financial results. The stock, however, rises 38% on news of funding raised by the company, which is expected to strengthen its cash position.
Highlights Strategic Progress and Clinical Developments
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided business highlights. "2023 was a year of significant progress across our broad thera
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced that the company has entered into a securities purchase agreement with certain existing accredited investors to issue and sell an aggregate of 3,244,689 shares of its comm
The infusion from unnamed private investors will bolster the company’s balance sheet days after a Sanofi-partnered ALS drug stumbled in a clinical trial.
Drug developer Denali Therapeutics said on Friday its and partner Sanofi's experimental drug for a fatal neurodegenerative disease failed to slow decline of motor function in a mid-stage study. Shares of Denali were down nearly 8% in morning trading. This marks the latest setback in the long list of roadblocks in the path to develop effective treatments against amyotrophic lateral sclerosis (ALS), a condition which affects 16,000 to 32,000 people in the United States, and almost completely par...